151450-20-3

Basic information

• Product Name: (3-(cyclopropylMethoxy)-4-(difluoroMethoxy)phenyl)Methanol
• Synonyms: (3-(cyclopropylMethoxy)-4-(difluoroMethoxy)phenyl)Methanol
• CAS NO: 151450-20-3
• Molecular Formula: C₁₂H₁₄F₂O₃
• Molecular Weight: 244.2345664
• Mol File: 151450-20-3.mol

Chemical Properties

• Boiling Point: 334.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.273±0.06 g/cm3(Predicted)
• PKA: 14.06±0.10(Predicted)
• CAS DataBase Reference: (3-(cyclopropylMethoxy)-4-(difluoroMethoxy)phenyl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-(cyclopropylMethoxy)-4-(difluoroMethoxy)phenyl)Methanol(151450-20-3)
• EPA Substance Registry System: (3-(cyclopropylMethoxy)-4-(difluoroMethoxy)phenyl)Methanol(151450-20-3)

Safety Data

• Hazardous Substances Data: 151450-20-3(Hazardous Substances Data)

Upstream product

• 162401-62-9 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzoic acid 
• 151103-08-1 4-difluoromethoxy-3-hydroxybenzaldehyde 
• 151103-09-2 3-(cyclopropylmethoxy)-4-(difluoromethoxy)-benzaldehyde 

Downstream Products

• 1428848-43-4 (S)-3,5-dichloro-4-(2-((3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzyloxy)carbonyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)pyridine 1-oxide 
• 153276-22-3 (3-cyclopropylmethoxy-4-difluoromethoxyphenyl)acetonitrile 
• 153587-18-9 3-cyclopropylmethoxy-4-difluoromethoxybenzyl chloride 

Relevant articles and documents

Design, synthesis and biological evaluation of substituted aminopyridazin-3(2H)-ones as G0/G1-phase arresting agents with apoptosis-inducing activities

A series of aminopyridazin-3(2H)-one derivatives has been designed and synthesized. Their antiproliferative activities were evaluated against three human cancer cell lines (SH-SY5Y human neuroblastoma, K562 human myelogenous leukemia and AGS gastric cancer cell lines) using the MTT assay. The preliminary activity test displayed that compound 8a exhibited comparable activities against all test cells with the positive control fluorouracil. Meanwhile compounds 8b, 8e and 9c-e displayed selective antiproliferative activities for SH-SY5Y cells. Furthermore, compounds 8a-b with low-micromole GI50 value for SH-SY5Y cells induced apoptosis with cell cycle arrest at G0/G1 phase in SH-SY5Y cells in a dose-dependent manner.

DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS

The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

DERIVATIVES OF 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOLS AS PHOSPHODIESTERASE INHIBITORS

The invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to compounds that are derivatives of 1-phenyl-2-pyridinyl alkyl alcohols, methods of preparing such compounds, compositions containing them and therapeutic use thereof.

Substituted pteridines for the treatment of inflammatory diseases

The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.

Synthesis and biological evaluation of imidazol-2-one and 2-cyanoiminoimidazole derivatives: novel series of PDE4 inhibitors.

This communication describes the synthesis and in vitro PDE4 inhibitory activity of a novel series of imidazol-2-one and 2-cyanoiminoimidazole derivatives. The compounds described were also tested in in vivo models to evaluate their anti-inflammatory activity after topical administration as well as their gastro-intestinal side effects. Several compounds proved to be potent PDE4 inhibitors and some 2-cyanoiminoimidazoles showed less pronounced gastro-intestinal side effects than reference compounds but maintained anti-inflammatory activity after topical administration.

Compounds useful for treating allergic or inflammatory diseases

Novel cyclohexanes of Formulas (I) and (II) STR1 are described herein. They inhibit the production of Tumor Necrosis Factor and are useful in the treatment of disease states mediated or exacerbated by TNF production; these compounds are also useful in the mediation or inhibition of enzymatic or catalytic activity of phosphodiesterase V.